167 related articles for article (PubMed ID: 35039091)
21. DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation.
Banerji CRS; Panamarova M; Zammit PS
Hum Mol Genet; 2020 Aug; 29(14):2285-2299. PubMed ID: 32242220
[TBL] [Abstract][Full Text] [Related]
22. PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle.
Banerji CRS; Panamarova M; Hebaishi H; White RB; Relaix F; Severini S; Zammit PS
Nat Commun; 2017 Dec; 8(1):2152. PubMed ID: 29255294
[TBL] [Abstract][Full Text] [Related]
23. Skeletal muscle regeneration in facioscapulohumeral muscular dystrophy is correlated with pathological severity.
Banerji CRS; Henderson D; Tawil RN; Zammit PS
Hum Mol Genet; 2020 Sep; 29(16):2746-2760. PubMed ID: 32744322
[TBL] [Abstract][Full Text] [Related]
24. Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy.
Greco A; Goossens R; van Engelen B; van der Maarel SM
Clin Genet; 2020 Jun; 97(6):799-814. PubMed ID: 32086799
[TBL] [Abstract][Full Text] [Related]
25. MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD.
Wang LH; Friedman SD; Shaw D; Snider L; Wong CJ; Budech CB; Poliachik SL; Gove NE; Lewis LM; Campbell AE; Lemmers RJFL; Maarel SM; Tapscott SJ; Tawil RN
Hum Mol Genet; 2019 Feb; 28(3):476-486. PubMed ID: 30312408
[TBL] [Abstract][Full Text] [Related]
26. Meeting report: The 2023 FSHD International Research Congress.
Arjomand J; Gabellini D; Voermans N;
Neuromuscul Disord; 2024 Feb; 35():53-57. PubMed ID: 37978033
[TBL] [Abstract][Full Text] [Related]
27. Meeting report: the 2020 FSHD International Research Congress.
Kyba M; Bloch RJ; Dumonceaux J; Harper SQ; van der Maarel SM; Sverdrup FM; Wagner KR; van Engelen B; Chen YW
Skelet Muscle; 2020 Dec; 10(1):36. PubMed ID: 33292505
[No Abstract] [Full Text] [Related]
28. DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?
Tassin A; Laoudj-Chenivesse D; Vanderplanck C; Barro M; Charron S; Ansseau E; Chen YW; Mercier J; Coppée F; Belayew A
J Cell Mol Med; 2013 Jan; 17(1):76-89. PubMed ID: 23206257
[TBL] [Abstract][Full Text] [Related]
29. Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update.
Schätzl T; Kaiser L; Deigner HP
Orphanet J Rare Dis; 2021 Mar; 16(1):129. PubMed ID: 33712050
[TBL] [Abstract][Full Text] [Related]
30. Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers.
van den Heuvel A; Lassche S; Mul K; Greco A; San León Granado D; Heerschap A; Küsters B; Tapscott SJ; Voermans NC; van Engelen BGM; van der Maarel SM
Sci Rep; 2022 Jan; 12(1):1426. PubMed ID: 35082321
[TBL] [Abstract][Full Text] [Related]
31. Deciphering transcription dysregulation in FSH muscular dystrophy.
Ehrlich M; Lacey M
J Hum Genet; 2012 Aug; 57(8):477-84. PubMed ID: 22718021
[TBL] [Abstract][Full Text] [Related]
32. Current Therapeutic Approaches in FSHD.
Wang LH; Tawil R
J Neuromuscul Dis; 2021; 8(3):441-451. PubMed ID: 33579868
[TBL] [Abstract][Full Text] [Related]
33. DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle.
Yao Z; Snider L; Balog J; Lemmers RJ; Van Der Maarel SM; Tawil R; Tapscott SJ
Hum Mol Genet; 2014 Oct; 23(20):5342-52. PubMed ID: 24861551
[TBL] [Abstract][Full Text] [Related]
34. Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy.
Bittel AJ; Sreetama SC; Bittel DC; Horn A; Novak JS; Yokota T; Zhang A; Maruyama R; Rowel Q Lim K; Jaiswal JK; Chen YW
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759720
[TBL] [Abstract][Full Text] [Related]
35. Facioscapulohumeral muscular dystrophy.
Tawil R
Handb Clin Neurol; 2018; 148():541-548. PubMed ID: 29478599
[TBL] [Abstract][Full Text] [Related]
36. Proteomics of Muscle Microdialysates Identifies Potential Circulating Biomarkers in Facioscapulohumeral Muscular Dystrophy.
Corasolla Carregari V; Monforte M; Di Maio G; Pieroni L; Urbani A; Ricci E; Tasca G
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396627
[TBL] [Abstract][Full Text] [Related]
37. Perturbation of muscle metabolism in patients with muscular dystrophy in early or acute phase of disease: In vitro, high resolution NMR spectroscopy based analysis.
Srivastava NK; Yadav R; Mukherjee S; Sinha N
Clin Chim Acta; 2018 Mar; 478():171-181. PubMed ID: 29278724
[TBL] [Abstract][Full Text] [Related]
38. Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings.
Jia FF; Drew AP; Nicholson GA; Corbett A; Kumar KR
Neuromuscul Disord; 2021 Nov; 31(11):1101-1112. PubMed ID: 34711481
[TBL] [Abstract][Full Text] [Related]
39. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo.
Wallace LM; Garwick SE; Mei W; Belayew A; Coppee F; Ladner KJ; Guttridge D; Yang J; Harper SQ
Ann Neurol; 2011 Mar; 69(3):540-52. PubMed ID: 21446026
[TBL] [Abstract][Full Text] [Related]
40. Transgenic zebrafish model of DUX4 misexpression reveals a developmental role in FSHD pathogenesis.
Pakula A; Lek A; Widrick J; Mitsuhashi H; Bugda Gwilt KM; Gupta VA; Rahimov F; Criscione J; Zhang Y; Gibbs D; Murphy Q; Manglik A; Mead L; Kunkel L
Hum Mol Genet; 2019 Jan; 28(2):320-331. PubMed ID: 30307508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
